Thus, the potential therapeutic use of rCD40L in NB patients may depend on preliminary in vitro assessment of caspase-8 activation in tumour cells under baseline conditions and following culture with demethylating agents or IFN-γ. This evidence concerns the gene IFNG and neoplasm.